Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • Patent number: 10738116
    Abstract: The invention provides dual specific chimeric antigen receptors (CARs) having antigenic specificity for CD19 and CD22. Nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Terry J. Fry, Crystal L. Mackall, Rimas J. Orentas, Waleed Haso, Haiying Qin
  • Patent number: 10738312
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: August 11, 2020
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10738313
    Abstract: The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: August 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: James N. Kochenderfer
  • Patent number: 10739427
    Abstract: The gradient coil assembly is designed to address a neck-shoulder clearance problem by configuring the coil holder housing with a cylindrical portion modified with a slanted surface and positioning current return elements of the coil pattern at the slanted surface, while positioning the active electrical elements on the cylindrical surface, thus eliminating influence of an undesired magnetic field generated by the current return elements, shortening the coil, and moving the homogeneous field gradient region toward the end of the cylindrical portion of the bore in the coil holder housing. The subject assembly operation is further improved by the direct external cooling approach, where a coolant flows in direct contact with electrical wires of the gradient coil inside the cooling channels in the surface of the coil holder housing.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: August 11, 2020
    Assignees: University of Maryland, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Bao Yang, Hanbing Lu, Zhi Yang
  • Patent number: 10737995
    Abstract: Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I: wherein R1 to R5 and X1 to X5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: August 11, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jane B. Neckers, Yeong Sang Kim, Sunmin Lee, Vineet Kumar, Sanjay V. Malhotra
  • Patent number: 10738365
    Abstract: Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-151. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-151. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: August 11, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Jeffrey A. Johnson, Walid M. Heneine, Jonathan T. Lipscomb, Xierong Wei
  • Publication number: 20200247901
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.
    Type: Application
    Filed: May 17, 2018
    Publication date: August 6, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Ira H. Pastan, Masanori Onda, Tapan Bera, Mitchell Ho
  • Publication number: 20200247869
    Abstract: Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Application
    Filed: April 2, 2020
    Publication date: August 6, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Eric Tran, Yong-Chen Lu, Anna Pasetto, Paul F. Robbins, Steven A. Rosenberg, Zhili Zheng
  • Patent number: 10730941
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: August 4, 2020
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Michel Sadelain, Reuben Benjamin, Dimiter S. Dimitrov, Yang Feng
  • Patent number: 10731204
    Abstract: The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: August 4, 2020
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Patent number: 10724007
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 28, 2020
    Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • Patent number: 10723787
    Abstract: The present invention relates to a novel antibody against HERV-K envelope that targets a conserved region not affected by glycosylation or by native conformation, and its use in diagnostics and/or in therapy.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: July 28, 2020
    Assignees: GENEURO SA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hervé Perron, Julie Medina, Avindra Nath, Joseph Perry Steiner, Wenxue Li, Myound-Hwa Lee
  • Patent number: 10722190
    Abstract: Disclosed herein are adaptive filters, radiographic systems, and methods for controlling the radiation exposure of a target object during a radiographic imaging procedure. An adaptive filter can comprise first and second dynamic collimators that block or attenuate radiation that is incident upon the collimators, but allow radiation to pass between the collimators to reach the target object and radiation detector. The collimators can move relative to each other during a radiation emission such that the motion of the collimators allows different amounts of radiation from the radiation source to pass between the two collimators to each portion of the target object during the radiation emission. The amounts of radiation allowed to reach each portion of the target object can be determined based on a thickness of each portion of the target object.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: July 28, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Andreu Badal-Soler
  • Patent number: 10723803
    Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: July 28, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, The United States of America, as represented by the Secretary, Department of Health and Human Services, The Regents of the University of California
    Inventors: Kipp Andrew Weiskopf, Kim J. Hasenkrug, Cheryl A. Stoddart, Joseph McCrary McCune, Irving L. Weissman
  • Publication number: 20200233099
    Abstract: Methods and apparatus for calibrating radioactive sources are described. An array of scintillation detectors forms a receptacle within which a sample or sample container can be retained by a holder. The scintillation detectors are coupled via light transducers such as photomultiplier tubes (PMTs) to independent electronic counters. Coincidence processing of time-tagged events yields a correlated event rate. One or more corrections can be applied as needed, for background counts, deadtime, or random coincidences. Voltage tuning of PMTs yields improved reproducibility. Accuracy of 1% has been demonstrated over a range of 10 kBq -3 MBq.
    Type: Application
    Filed: September 4, 2018
    Publication date: July 23, 2020
    Applicant: THE UNITED STATES OF AMERICA,as Represented by the Secretary, Department of Health and Human Service
    Inventor: Stephen S. Adler
  • Patent number: 10716809
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+ T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: July 21, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Publication number: 20200223937
    Abstract: Disclosed is a molecule comprising: (a) a first domain, which comprises a targeting moiety; (b) a second domain, which comprises an albumin binding domain (ABD), (c) a third domain, which comprises a furin cleavage sequence (“FCS”), which FCS is cleavable by furin; and (d) a fourth domain, which comprises an optionally substituted Domain III from Pseudomonas exotoxin A (“PE”). Related nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, methods of producing the molecule, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Application
    Filed: September 18, 2018
    Publication date: July 16, 2020
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Ira H. Pastan, Junxia Wei, Masanori Onda, Tapan Bera, Mitchell Ho
  • Patent number: 10711068
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties; products, compositions and kits comprising the monoclonal antibodies; methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: July 14, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Patent number: 10709790
    Abstract: The present invention is directed to a compound of Formula I or Formula II or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: Formula I Formula II The compounds of Formula I may be covalently bonded to a therapeutic compound or fragment thereof to provide a compound of Formula II and thereby extend the half-life of the therapeutic compound. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use in the diagnosis or treatment of diseases.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: July 14, 2020
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Xiaoyuan Chen, Lixin Lang, Gang Niu
  • Patent number: 10712545
    Abstract: Systems and methods for conducting contact-free thickness and refractive-index measurements of transparent objects, such as intraocular lenses using a dual confocal microscopy system are disclosed.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: July 14, 2020
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Do-Hyun Kim, Ilko Kolev Ilev, Robert Harold James, Don Calogero